BofA lowered the firm’s price target on Acumen (ABOS) to $9 from $10 and keeps a Buy rating on the shares, citing the updated cash position following a Q2 report the firm calls “(understandably) quiet.” The “key update” was the phase 2 ALTITUDE-AD of sabirnetug in early AD remains on track to read-out late 2026, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: